I thought I'd just take a moment to talk about what I'm finding with regard to ALK rearrangements in patients with NSCLC (see here for review). I hope and expect that there will be more to learn at the ASCO conference in early June, either in the setting of official presentations on the subject or through informal discussions with my colleagues who are also involved with this work.

Last week, Dr. Ross Camidge from the University of Colorado joined me on a webinar entitled "One Size Does Not Fit All" in which he discussed the early work on ALK rearrangements and the novel agent PF-02341066 (now known as crizotinib) in particular, and the new era of molecularly defined practice of oncology in particular. This story has been widely considered to be among the most important in the field of lung cancer over the last few years, and Dr. Camidge did not disappoint.